The city says the first center closed in May after treating 1,076 patients to keep them out of the hospital with severe COVID-19 symptoms. Previously, it had been giving both Regeneron and Bamlanivimab, depending on availability. The U.S. Food and Drug Administration has 1/2
since stopped recommending Bamlanivimab, which was administered mixed with another drug, because it wasn’t fully effective against current variants. 2/2 kxan.com/news/local/aus…
Currently, COVID-19 infusion therapy is dispensed through an IV.
Company is TFF Pharmaceuticals. The technology was developed by University of Texas researcher Bill Williams. The antibody called Aug-3387 is converted into dry powder and then put inside the inhaler. kxan.com/news/coronavir…
The treatment is aimed mainly at patients whose health conditions, age or weight place them at especially high risk of severe disease. But eligibility includes so many more-moderate risk factors, including merely being overweight... 1/2 bloomberg.com/news/articles/…
2/2 that fully 70% of the U.S. population qualifies.
@GovAbbott tests positive for #covid19 today and is receiving Regeneron's monoclonal antibody treatment. #regeneron